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Antiangiogenic therapy may prolong the dormancy of cancer le-
sions. Moreover, radioimmunotherapy (RIT) may eradicate this
population of cells. This study dealt with determining the benefits
associated with the combined usefulness of these 2 therapies with
respect to inhibition of tumor growth. Methods: Antiangiogenic
therapy using oral thalidomide (daily dose, 200 mg/kg) and RIT
involving a single intravenous injection (4.63 MBq 131I-A7, an IgG1
murine monoclonal antibody) were conducted in mice bearing
LS180 human colon cancer xenografts. RIT with an irrelevant IgG1,
HPMS-1, was also performed as a control. Antiangiogenesis of
thalidomide was investigated by immunohistochemical analysis of
tumor sections. Results: Antiangiogenic therapy and RIT with
131I-A7 significantly suppressed the growth of xenografts. This
combination produced more efficient tumor growth inhibition than
did the monotherapy (P  0.005). RIT using 131I-HPMS-1 was far
less effective than 131I-A7, even when combined with thalidomide
administration. Immunohistochemistry revealed a decrease in the
microvessel number within tumors treated with thalidomide (P 
0.0001). Combined therapy further reduced the microvessel num-
ber (P  0.01 vs. thalidomide monotherapy). Conclusion: The
combination of RIT and thalidomide antiangiogenic therapy pro-
duces a better response of tumors than does monotherapy. Acting
in concert, antiangiogenic therapy may prolong the dormancy of
cancer lesions and RIT may eradicate this population of cells.
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Theoretically, radioimmunotherapy (RIT) may selec-
tively treat cancer lesions; moreover, systemic administra-
tion of radiolabeled monoclonal antibody (mAb) may en-
able the treatment of disseminated metastatic lesions.
However, results reported for conventional RIT in most
solid tumors, with the exception of malignant lymphoma,
have not been favorable (1). Consequently, modification of
RIT is considered to effect killing of solid tumors (1).
Tumor growth depends on neoangiogenesis; therefore,
antiangiogenic therapy using agents that suppress endothe-
lial cell growth has been investigated extensively (2). The
objective of this treatment is to maintain lesions at limited
size, a situation referred to as tumor dormancy (2). We
hypothesize that the combined usefulness of antiangiogenic
therapy and RIT may synergistically effect treatment of
cancer lesions. The rationale for this hypothesis is based on
the suppression of tumor endothelial compartments by an-
tiangiogenic agents as well as the direct action of RIT
against tumor cells. In addition, antiangiogenic therapy in-
duces dormancy of lesions and RIT may eradicate this
population of dormant cells.
Thalidomide was developed as a sedative; however, it
was subsequently withdrawn from clinical use because of its
teratogenicity. This agent is now known to exert effects on
the immune system. Thalidomide inhibits the production of
tumor necrosis factor-, stimulates cytotoxic T-cell prolif-
eration, and induces secretion of interferon- and interleu-
kin-2 (3,4). On the basis of its antiinflammatory properties,
thalidomide is used in the treatment of such diseases as
erythema nodosum leprosum and graft-versus-host disease.
In addition, thalidomide possesses potent antiangiogenic
properties (5–7), which arise as a result of blockade of the
action of angiogenic factors such as vascular endothelial
growth factor (VEGF) (8) and basic fibroblast growth factor
(bFGF) (5). Consequently, this agent is being investigated
currently in clinical trials of patients exhibiting various
types of malignancies (3,4). This study dealt with determin-
ing the effects of combined RIT and thalidomide therapy in
the treatment of xenografts of human colon cancer cells.
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MATERIALS AND METHODS
mAb and Tumor Model
A7, an IgG1 murine mAb with -light chain, was used in this
investigation (9). It was purified from ascites of hybridoma-bear-
ing mice by protein A–Sepharose column (Bio-Rad, Richmond,
CA) chromatography. A7 mAb recognizes a 45-kDa surface gly-
coprotein of human colonic carcinomas. An additional IgG1 rec-
ognizing placental alkaline phosphatase, HPMS-1, was used as a
class-matched irrelevant control mAb (10). The mAbs were radio-
labeled with 131I by the chloramine-T method and subsequently
purified on a PD-10 column (Pharmacia LKB Biotechnology,
Uppsala, Sweden). The specific activity of purified 131I-A7 was
142 MBq/mg. Immunoreactivity of purified 131I-A7 was assessed
as 69% in antigen excess conditions with an LS180 human colon
cancer cell line. The specific activity of 131I-HPMS-1 was 90
MBq/mg. Antibodies were sterilized by filtration (Millex-GV, 0.22
mm; Millipore, Bedford, MA) before further experiments. Animal
studies were performed in compliance with the regulations of our
institutions, and the principles of laboratory animal care were
followed. BALB/c nu/nu mice (female, 6–8 wk old) were xe-
nografted subcutaneously in the thigh area with 5  106 LS180
cells. Animals were subjected to treatment when xenografts at-
tained a diameter of approximately 5–7 mm. This cell line report-
edly shows considerable VEGF production; moreover, the growth of
xenografts in mice is suppressed by an anti-VEGF antibody (11).
Antitumor Effect of 131I-A7 with Thalidomide
Tumor volume (mm3), calculated as length (mm)  width
(mm)2  0.5, was expressed as a ratio of volumes to the volume
obtained on the initial day of treatment (day 0). Tumor volume on
day 0 was measured as 139 21 mm3. The therapeutic experiment
consisted of 6 groups: nontreated mice (n  5); mice receiving a
daily oral dose of 200 mg/kg thalidomide (n  10); mice under-
going treatment with 4.63 MBq 131I-A7 (n 10); mice treated with
131I-A7 and a daily dose of thalidomide (n 10); mice treated with
4.63 MBq of an irrelevant mAb, 131I-HPMS-1 (n  5); and mice
receiving 131I-HPMS-1 and a daily dose of thalidomide (n  6).
Thalidomide suspensions were prepared in 0.1 mL 0.5% car-
boxymethylcellulose (Wako, Osaka, Japan) and administered
orally. The dose of 131I-A7 used in this study was approximately
half of the maximum tolerated dose in this model. Thalidomide
dosage was determined in accordance with previous reports (5–7).
This dosage has not been reported to cause critical side effects.
Nontreated mice and mice receiving RIT monotherapy were orally
administered an identical volume of carboxymethylcellulose that
did not contain thalidomide. The therapeutic efficacy of each
treatment was analyzed statistically by tumor size on day 13.
Furthermore, analysis with the area under the curve (AUC) of
tumor growth curves, which would be the reflection of the thera-
peutic effect during the entire observation period, was also per-
formed for the comparison among the treatment groups.
Toxicity of Treatment
A major critical organ in RIT is the bone marrow. Thalidomide
may cause neutropenia (3). Therefore, we attempted to establish
whether the combined therapy increased myelotoxicity in animals.
Nontumor-bearing mice were partitioned into 4 groups: nontreated
mice, mice receiving RIT (4.63 MBq), mice treated with a daily
dose of thalidomide (200 mg/kg), and mice undergoing the com-
bined regimen (n 3). Thalidomide administration was conducted
until day 23. A blood sample (5 L) was obtained from a tail vein
in each mouse. Samples from mice within a single group were
pooled and diluted 1:10,000 in phosphate-buffered saline for red
blood cell (RBC) counts, 1:20 in 3% acetic acid for white blood
cell (WBC) counts, and 1:100 in 1% ammonium oxalate for
platelet counts (12). Body weight of the animals was also deter-
mined.
Assessment of Microvessel Density in Tumors
Tumors were excised from nontreated control mice, mice
treated with either thalidomide or 131I-A7 RIT monotherapy, and
mice treated with the combined therapy on day 15. Specimens
were fixed with 10% formalin and embedded in paraffin wax (n 
3). Immunoperoxidase staining using a rabbit polyclonal antibody
against factor VIII (DAKO, Copenhagen, Denmark) was per-
formed. The microvessel density was determined by light micros-
copy according to the procedure described by Weidner et al. (13).
Briefly, the areas of highest vascularization were detected by
low-power scanning (100) of the tumor sections. Individual
microvessels were then counted in a 200 field, with 5 different
fields examined in each section. Two sections per tumor were
studied, and the average of 3 tumors in each group was compared.
In Vitro Assay with Thalidomide
Cells were incubated in 24-well culture plates at 20,000 cells
per milliliter in Dulbecco’s modified Eagle medium (Nissui Sei-
yaku, Tokyo, Japan) to determine whether thalidomide would
exert a direct effect on LS180 cell growth. Increasing concentra-
tions of thalidomide (up to 100 mol/L) were introduced. The
agents were dissolved in dimethyl sulfoxide ([DMSO]; Wako,
Tokyo, Japan) and diluted in the medium. The final concentration
of DMSO was 0.5%. Control cells were treated with DMSO alone.
Before the assay, confirmation was obtained that DMSO at this
concentration did not affect proliferation of LS180 cells. Cells
were exposed to trypsin, and the viable cell number was then
determined 1, 3, and 5 d after inoculation (n  3).
The possibility of radiosensitization effects of thalidomide on
LS180 cells was investigated. Briefly, cells were treated with
thalidomide at various concentrations up to 100 mol/L for 24 h,
followed by exposure to an x-ray beam (0–8 Gy) (MBR-1520R;
Hitachi, Tokyo, Japan) at 1.41 Gy/min. Cell proliferation was
observed, and the surviving fraction was calculated as described
(14).
Statistical Analysis
Results were analyzed by 1-way ANOVA with Fisher’s pro-
tected least-significant difference. The level of significance was set
at 5%.
RESULTS
Either thalidomide or 131I-A7 RIT monotherapy signifi-
cantly suppressed growth of LS180 xenografts in compari-
son with no treatment (P  0.005 and P  0.0005, respec-
tively) (Fig. 1). Relative tumor volumes on day 13 were
12.7  2.95, 6.84  0.71, and 3.05  0.37 in the control
group, the group administered thalidomide, and the group
receiving 131I-A7 RIT, respectively. Treatment with a class-
matched irrelevant mAb, 131I-HPMS-1, did not effectively
suppress tumor growth (P 0.06). The combined treatment
of thalidomide and 131I-A7 RIT resulted in more efficient
tumor growth inhibition than did monotherapy with thalid-
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omide or RIT alone, displaying a tumor volume of 1.31 
0.33 on day 13 (P  0.005 vs. RIT alone). Moreover, 6 of
10 tumors regressed with combined treatment, whereas no
regression occurred with monotherapy. Results of AUC
analysis of tumor growth curves also indicated the superi-
ority of the combined regimen of thalidomide and 131I-A7
RIT over monotherapy for the inhibition of tumor growth
(Table 1). The combination of 131I-HPMS-1 and thalido-
mide was far less effective than the combination of 131I-A7
and thalidomide.
Thalidomide treatment induced minor depression of the
peripheral WBC count relative to that observed in non-
treated mice (Fig. 2). The nadir of WBC count depression in
mice treated with the combination of RIT and thalidomide
FIGURE 2. Changes in peripheral blood cell counts in mice.
(A) RBCs; (B) WBCs; (C) platelets. , Nontreated control; Œ,
tumors treated with 200 mg/kg/d thalidomide; E, tumors treated
with 4.63-MBq RIT; F, tumors treated with thalidomide and RIT.
FIGURE 1. Growth of LS180 colon cancer xenografts. Tumor
volume is expressed as ratio relative to volume on day 0. ,
Nontreated control; Œ, tumors treated with 200 mg/kg/d thalid-
omide; , tumors treated with 4.63 MBq 131I-HPMS-1; f, tu-
mors treated with thalidomide and 131I-HPMS-1; E, tumors
treated with 4.63 MBq 131I-A7; F, tumors treated with thalido-
mide and 131I-A7.
TABLE 1
Analysis of AUC of Growth Curves of Colon Cancer
Xenografts After Initiation of Treatment
Treatment n AUC for 13 d
Control 5 82.5  30.7
Thalidomide 10 50.5  15.5*
HPMS-1 5 58.6  26.1†
HPMS-1 	 thalidomide 6 43.0  5.64‡
A7 10 29.6  8.24§
A7 	 thalidomide 10 14.7  7.04¶
* P  0.001 vs. control.
† P  0.05 vs. control.
‡ Not significant vs. thalidomide or HPMS-1.
§ P  0.0001 vs. control and P  0.01 vs. thalidomide.
¶ P  0.05 vs. A7.
Thalidomide 200 mg/kg/d; HPMS-1 131I-irrelevant mAb (4.63
MBq); A7  131I-specific mAb (4.63 MBq).
Data are expressed as mean  SD.
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therapy was similar to that in mice treated with RIT alone;
however, the depression persisted in mice treated with the
combination regimen. The WBC count recovered after the
cessation of thalidomide administration. Changes in the
platelet count in mice receiving the combination treatment
did not vary from those in mice undergoing RIT alone.
Thalidomide administration did not affect the RBC count.
The use of thalidomide did not result in weight loss that was
different than that of the control (Fig. 3). The maximal body
weight loss was similar in mice treated with RIT alone and
those undergoing the combination regimen; however, re-
covery was delayed by thalidomide treatment. No mice
showed signs of diarrhea or infection.
Immunostaining of tumor sections with antifactor VIII
antibody showed significant reduction in the microvessel
density in tumors treated with thalidomide (8.30  0.8 per
200 field) in comparison with nontreated control tumors
(29.9  2.5) (P  0.0001) (Fig. 4). Interestingly, the mi-
crovessel density in tumors treated with 131I-A7 RIT
(10.8  1.4) was lower than that in control tumors (P 
0.0001). Moreover, the combination of RIT and thalidomide
treatment further decreased the microvessel density in tu-
mors (4.3  0.5; P  0.0001 vs. RIT monotherapy and P 
0.01 vs. thalidomide monotherapy).
The in vitro proliferation assay revealed no evidence of
direct cytotoxicity of thalidomide in LS180 cells up to
concentrations of 100 mol/L (Fig. 5). In addition, thalid-
omide did not radiosensitize the cells (Fig. 6).
DISCUSSION
Thalidomide is currently being investigated in several
clinical trials involving tumors such as low-grade glioma,
AIDS-related Kaposi’s sarcoma, renal cell carcinoma, hep-
atocellular carcinoma, and multiple myeloma (3). The ef-
fectiveness of thalidomide in colorectal cancer patients is
also currently being evaluated (3). It is known that the
degree of tumor vascularization is a prognostic factor of
colon cancer and is correlated with its metastases and re-
currence (15). Expression of VEGF and bFGF also corre-
lates with prognosis in colon cancer patients (16). A neu-
tralizing anti-VEGF mAb exhibits antitumor activity in
xenografts of various colon cancer cell lines (11). In our
study, the tumor-suppressive effects of thalidomide were
detected in xenografts of LS180 colon cancer cells. These
FIGURE 3. Body weight changes of mice. , Nontreated
control; Œ, tumors treated with 200 mg/kg/d thalidomide; E,
tumors treated with 4.63-MBq RIT; F, tumors treated with tha-
lidomide and RIT.
FIGURE 4. Immunohistochemistry of tu-
mor sections with an antifactor VIII anti-
body. Microvessel numbers in 200 field
are 29.9  2.5 in control tumor (A) and
8.30  0.8 in tumor treated with thalido-
mide (B) (P  0.0001).
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facts suggest a role for antiangiogenic therapy in patients
with colon cancer. However, because the response rates of
solid tumors to monotherapy with thalidomide are limited in
clinical trials, the combination with chemotherapy or radio-
therapy has been considered. The efficacy of conventional
RIT is also currently limited in most types of tumors;
consequently, several methods have been proposed to im-
prove its therapeutic outcome (1).
The combination of antiangiogenic therapy and RIT pro-
posed in this investigation is a novel approach in which 2
agents act against distinct compartments within tumors:
Antiangiogenic agents suppress the endothelial compart-
ment, whereas RIT acts directly against the tumor cell. We
showed that thalidomide was unable to exert direct cytotox-
icity on LS180 cells or to sensitize cells to radiation; how-
ever, thalidomide reduced the microvessel density in xeno-
grafts in mice. These results clearly indicate that the
cooperative improvement of tumor growth suppression with
combined therapy was related to this hypothesis. The effec-
tiveness of combining RIT and another antiangiogenic
agent, 2-methoxyestradiol, has been reported recently (17).
Interestingly, 131I-A7 RIT monotherapy reduced the mi-
crovessel number in tumors compared with no treatment;
furthermore, the combined regimen more effectively de-
creased the microvessel number than did thalidomide mono-
therapy. These findings were probably caused by radiation
injury of the vessels due to 131I-A7. Because penetration of
extravasated mAbs into solid tumors is disturbed by factors
such as high interstitial pressure (18) and the so-called
binding site barrier (19), mAbs would deposit close to the
vasculature; for instance, IgG would require days to cover
the distance of 
1 mm after the extravasation (18). Conse-
quently, considerable radiation dose would be absorbed by
the vascular compartment. In this sense, RIT and antiangio-
genic therapy would cooperatively give effect to suppres-
sion of the tumor vasculature in the combined regimen.
Changes in peripheral blood cell counts and the body
weight of mice were monitored to assess the toxicity of
treatment. In addition to teratogenicity, thalidomide dis-
plays several adverse effects, including somnolence, consti-
pation, skin rashes, orthostatic hypotension, nausea, periph-
eral neuropathy, and neutropenia (3,4). Most of these
untoward effects do not occur in RIT therapy; however,
neutropenia may affect combination with RIT. Minor de-
pression of the peripheral WBC count was observed in mice
that were treated daily with thalidomide. The combined
regimen delayed recovery of the WBC count in comparison
with RIT monotherapy. Recovery of body weight loss was
also delayed by this combination. Reports describing clini-
cal trials of thalidomide indicate that thalidomide-induced
neutropenia occurs rarely in patients other than those pre-
senting with HIV infection and recipients of an allogeneic
bone marrow transplant (3,4); however, marrow toxicity
should be carefully monitored during combination therapy
involving RIT and thalidomide.
Clinical results of RIT have been disappointing in the
treatment of bulky disease of solid tumors (1). However,
several reports have described the role of RIT in an adjuvant
setting of cancer treatment, in which small residual tumors
are targeted by mAbs (20–23). Antiangiogenic therapy also
has an important role in this setting, in which angiogenesis
inhibitors may induce dormancy of microscopic metastases
or stabilization of residual disease (24–26). Because anti-
FIGURE 6. Clonogenic assay of LS180 colon cancer cells
exposed to x-ray radiation (n  3). , Control cells; cells pre-
treated with thalidomide for 24 h: f, 1 mol/L; Œ, 10 mol/L; ✖,
100 mol/L.
FIGURE 5. In vitro proliferation assay of LS180 colon cancer
cells in presence of increasing concentrations of thalidomide
(n  3). f, Without thalidomide; in presence of thalidomide: F,
0.1 mol/L; Œ, 1 mol/L; , 5 mol/L; , 10 mol/L; E, 50
mol/L; ‚, 100 mol/L.
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angiogenic therapy alone may not produce a complete cure,
a combination with cytotoxic therapy is required to be
curative (1). In this regard, a combined regimen with exter-
nal beam radiotherapy has been proven to enhance tumor
growth suppression in various kinds of tumors (27,28).
However, as a local treatment, external beam radiotherapy
should have a limitation in patients with metastatic foci. The
combined regimen with RIT and antiangiogenic therapy
surely has an advantage in this setting, because both treat-
ments can be administered systemically.
CONCLUSION
We observed a cooperative relationship in the combined
usefulness of RIT and antiangiogenic therapy with thalido-
mide in the treatment of colon cancer xenografts. Acting in
concert, antiangiogenic therapy may prolong the dormancy
of cancer lesions and RIT may eradicate this population of
cells. We are currently testing this hypothesis in liver me-
tastasis and intraperitoneal metastasis models.
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